相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Biochemistry & Molecular Biology
Jia Wei et al.
Summary: This study investigated the antibody responses and protection following the second doses of ChAdOx1 or BNT162b2 vaccines against SARS-CoV-2 in the general population of the United Kingdom. The results showed significant boosting of anti-spike IgG antibody levels after the second doses of both vaccines, with BNT162b2 generating higher peak levels than ChAdOX1. Older individuals, males, and prior infection influenced the antibody levels. The levels of anti-spike IgG were associated with protection from infection after vaccination, and previous infection enhanced antibody peak levels and half-life. At least 67% protection against infection is estimated to last for 2-3 months after two ChAdOx1 doses, 5-8 months after two BNT162b2 doses in uninfected individuals, and 1-2 years after natural infection in unvaccinated individuals. A third booster dose may be necessary, prioritizing ChAdOx1 recipients and those more clinically vulnerable.
Article
Medicine, General & Internal
Victoria Hall et al.
Summary: This study investigated the duration and effectiveness of immunity among healthcare workers in the United Kingdom. It found that two doses of the BNT162b2 vaccine provided high short-term protection against SARS-CoV-2 infection, but this protection significantly decreased after six months. However, infection-acquired immunity boosted by vaccination remained high, even more than one year after infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Infectious Diseases
Edgar A. Melgoza-Gonzalez et al.
Summary: The SARS-CoV-2 virus, first detected in Wuhan, China in December 2019, has led to the rapid development of diagnostic tools, therapies, and vaccines to control COVID-19. ELISA antibody detection has been widely used to recognize infection and vaccine response. Research showed that IgG antibodies can be detected up to 42 weeks after natural infection, and that one dose of CanSinoBio vaccine induces a lower IgG antibody response compared to the complete Pfizer-BioNTech vaccine regimen.
TRANSBOUNDARY AND EMERGING DISEASES
(2022)
Article
Immunology
David Goldblatt et al.
Summary: This study measured immune responses to four COVID-19 vaccines and found a significant correlation between IgG anti-Spike antibodies and neutralization of the virus, as well as protection against infection. The protective threshold for each vaccine was calculated, providing a potential method for evaluating the efficacy of new vaccines.
Article
Biotechnology & Applied Microbiology
Ibrahim Mohammed et al.
Summary: This article compares the efficacy and effectiveness of seven COVID-19 vaccines through a systematic review, revealing that these vaccines have successfully reduced infection rates, severity, hospitalization, and mortality. The full-dose regimen of the Pfizer/BioNTech vaccine shows the highest effectiveness against various variants.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Public, Environmental & Occupational Health
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2022)
Article
Urology & Nephrology
Ilias Bensouna et al.
Summary: The effectiveness of a third dose of the BNT162b2 vaccine in patients undergoing dialysis treatment was investigated, and it was found that the third dose significantly increased antibody levels.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2022)
Editorial Material
Medical Laboratory Technology
Mario Plebani et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2022)
Article
Infectious Diseases
Xinxue Liu et al.
Summary: The decay rates of humoral response differ between vaccines 84 days after a third dose of COVID-19 vaccine. The anti-spike IgG concentrations following BNT/BNT initial doses were similar to or higher than for a three-dose BNT schedule. Half dose BNT immune responses were similar to full dose responses.
JOURNAL OF INFECTION
(2022)
Article
Infectious Diseases
Cristina Menni et al.
Summary: This study aimed to investigate the effectiveness and waning of COVID-19 primary vaccine series, as well as the safety and effectiveness of booster doses. The results showed that vaccine effectiveness decreased after the second dose, but booster doses restored effectiveness. However, heterologous booster regimens had more systemic side-effects.
LANCET INFECTIOUS DISEASES
(2022)
Letter
Medicine, General & Internal
Gili Regev-Yochay et al.
Summary: Health care workers in Israel received a fourth dose of mRNA vaccine during the prevalence of the omicron variant. The fourth dose boosted antibody levels but did not surpass the maximum observed after the third dose. The vaccine demonstrated an efficacy of 31 to 43% against symptomatic disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Milja Belik et al.
Summary: Vaccination demonstrates effectiveness in protecting against COVID-19, with ongoing optimization of regimens and dosages. Research shows that a third dose of COVID-19 mRNA vaccines may induce cross-protective neutralizing antibodies against multiple variants.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Bruna Lo Sasso et al.
Summary: Assessing anti-S-RBD IgG levels is essential for monitoring long-term antibody response. A third dose of the SARS-CoV-2 vaccine induces a strong immunological response, supporting the efficacy of the vaccine programs and the usefulness of the third dose.
SCIENTIFIC REPORTS
(2022)
Editorial Material
Medicine, General & Internal
Gavin Yamey et al.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Public, Environmental & Occupational Health
Alejandro Jara et al.
Summary: This study evaluated the effectiveness of booster vaccine doses against COVID-19 in individuals who had completed a primary immunisation schedule with CoronaVac. The results showed that a homologous or heterologous booster dose provides a high level of protection against COVID-19, including severe disease and death. Heterologous boosters showed higher vaccine effectiveness than a homologous booster for all outcomes, providing additional support for a mix-and-match approach.
LANCET GLOBAL HEALTH
(2022)
Article
Infectious Diseases
Frauke Muecksch et al.
Summary: Neutralising antibody titres in individuals with SARS-CoV-2 infection decrease over the first few months post-infection but stabilise thereafter at about 30% of the initial level. Serological assays commonly used to measure antibodies against SARS-CoV-2 display varying sensitivities that decline over time. Serological assays based on the spike protein are better at predicting neutralising antibody titres compared to assays based on nucleocapsid, but there is variability in performance and manufacturer positivity thresholds are not reliable indicators of neutralising activity.
Article
Infectious Diseases
Oliver J. Watson et al.
Summary: A study quantified the global impact of the first year of COVID-19 vaccination programs, finding that the vaccination has substantially altered the course of the pandemic, saving tens of millions of lives globally. However, inadequate access to vaccines in low-income countries has limited the impact, reinforcing the need for global vaccine equity and coverage.
LANCET INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Tal Patalon et al.
Summary: In this retrospective study, the authors demonstrate a significant waning of mRNA vaccine effectiveness against the Omicron variant of SARS-CoV-2 infection within a few months after administration of the third dose of the BioNTech/Pfizer BNT162b2 vaccine.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Nuri Lee et al.
Summary: This study quantitatively analyzed the levels of SARS-CoV-2 antibodies in patients who received two doses of ChAdOx1 nCoV-19 vaccine and a third dose of BNT162b2 booster. The results showed that the antibody levels significantly decreased in the non-infected group after 4 months of the third dose, while the infected group had higher antibody levels during the same period. The antibody levels in the infected group were correlated with the number of days after SARS-CoV-2 infection.
Article
Medicine, General & Internal
Mayan Gilboa et al.
Summary: This study found that the third dose of the vaccine provided greater durability compared to the second dose; however, Omicron showed greater resistance to neutralization compared to the wild type and Delta variants. The dynamics of humoral response were associated with susceptibility to Omicron infection.
Article
Medicine, General & Internal
Oon Tek Ng et al.
Summary: This cohort study assessed the effectiveness of booster vaccinations against severe COVID-19 and confirmed SARS-CoV-2 infection in Singapore during the Omicron wave. The study found that mRNA boosters provided protection against confirmed infection for 15 to 60 days, but the effectiveness waned after five months. mRNA boosters also showed high effectiveness against severe COVID-19. Three-dose inactivated SARS-CoV-2 vaccination provided greater protection than two-dose, but weaker protection compared to mRNA boosters.
Article
Health Care Sciences & Services
Erika Molteni et al.
Summary: One dose of BNT162b2 vaccine reduces the risk of SARS-CoV-2 infection in children and adolescents aged 12-17 years. The severity of disease after vaccination is generally milder, but unvaccinated children and adolescents also have generally mild disease. Post-vaccination local side-effects are common, systemic side-effects are uncommon, and both resolve within a few days.
LANCET REGIONAL HEALTH-EUROPE
(2022)
Article
Immunology
Chin Shern Lau et al.
Summary: This study compares the early spike protein antibody and neutralizing antibody responses to two vaccines. The results show that mRNA vaccines generate a more robust antibody response at all time points.
Article
Medicine, General & Internal
Seok Ryun Kwon et al.
Summary: Despite strict COVID-19 guidelines, South Korea is experiencing its fourth wave. Antibody titers decreased over time post-second vaccine dose, but increased significantly after booster doses, especially for low responders to the second dose. This study provides evidence for the efficacy of booster vaccinations and can inform vaccination policy decisions.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2022)
Article
Infectious Diseases
Oliver J. Watson et al.
Summary: The study estimated that COVID-19 vaccination has prevented millions of deaths globally between December 8, 2020, and December 8, 2021. Achieving the vaccination coverage targets set by COVAX and WHO could have prevented even more deaths. However, limited access to vaccines in low-income countries has hindered the impact, highlighting the importance of global vaccine equity.
LANCET INFECTIOUS DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Shuo Feng et al.
Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.
Article
Immunology
Chin-Shern Lau et al.
Summary: The study revealed that COVID-naive subjects from Southeast Asia showed sustained and elevated antibody responses post COVID-19 vaccination. Majority of the participants tested positive for antibodies 10 days after dose 1, with a small percentage showing neutralizing antibody positivity. Even at 180 days, some antibodies remained active, with neutralizing antibody titers expected to stay reactive up to 241 days post-vaccination.
Article
Multidisciplinary Sciences
Nina Lagerqvist et al.
Summary: The evaluation of 11 SARS-CoV-2 antibody tests showed heterogeneity in their performances, with only a few tests performing well with samples having low IFA IgG titers. It is crucial to carefully select tests for accurate diagnostics and epidemiological investigations.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Rishi R. Goel et al.
Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.
SCIENCE IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Elizabeth Fraley et al.
Summary: This study characterized humoral immune responses during vaccination with the BNT162b2 vaccine in individuals with or without prior history of natural SARS-CoV-2 infection, demonstrating differences in antibody levels and epitope specificity between the two groups. The findings support the consideration of prior infection history as a guide for future vaccination strategies and provide valuable insights for vaccine development.
Article
Medical Laboratory Technology
Silvia Meschi et al.
Summary: The study found a significant correlation between antibody response and virus neutralization titer, with 2,000 BAU/mL serving as a predictive threshold for strong neutralization response in vaccinated individuals.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Talia Kustin et al.
Summary: Breakthrough SARS-CoV-2 infections post-vaccination may be caused by B.1.1.7 or B.1.351 variants, indicating the importance of robust vaccination. Reduced vaccine effectiveness against these variants was observed in the study, highlighting the need for continued surveillance and enhanced vaccination efforts.
Article
Medical Laboratory Technology
C. S. Lau et al.
Summary: The study evaluated the performance of the Abbott SARS-CoV-2 IgM assay on the Architect immunoassay analyser, showing good specificity and no cross-reactivity with other antibody-positive cases. The combined IgM and IgG results demonstrated better sensitivity in early COVID-19 compared to the Cobas total antibody assay, with good agreement between the Architect and Cobas assays.
PRACTICAL LABORATORY MEDICINE
(2021)
Article
Immunology
Julien Favresse et al.
Summary: The study aimed to assess the antibody response in healthcare professionals who had received the BNT162b2 mRNA COVID-19 vaccine, finding a decline in antibody levels at 3 months post-vaccination but maintaining a robust immune response.
EMERGING MICROBES & INFECTIONS
(2021)
